On June 24, 2026, the House Science, Space, and Technology Committee’s Subcommittee on Investigations and Oversight held a hearing titled “Safeguarding Federal Research Funds: The False Claims Act’s Role in Combating Grant Fraud.” The hearing brought federal watchdogs and a Department of Justice official together to examine how the False Claims Act (FCA) is being applied to federal research grants, and it surfaced a theme research administrators should watch closely: undisclosed foreign affiliations as a growing enforcement target.
This piece is a news update layered on top of CASRAI’s existing guide to the False Claims Act in research grant compliance — read that guide for the underlying legal mechanics (qui tam provisions, treble damages, materiality standard); this page covers what the hearing specifically added to the picture.
Who testified, and what the hearing covered
The subcommittee, chaired by Rep. Rich McCormick (R-GA), heard from three witnesses: Brenna Jenny, Deputy Assistant Attorney General for DOJ’s Commercial Litigation Branch; Jennifer Springmann, Special Agent in Charge at the National Science Foundation Office of Inspector General; and Robert Steinau, Senior Official Performing the Duties of Inspector General at NASA’s Office of Inspector General.
Testimony and questioning centered on three recurring compliance failure modes the FCA has been used to pursue in the research-funding context:
- False certifications made by institutions or investigators to obtain or retain federal funding.
- Failure to disclose foreign funding, foreign affiliations, and related conflicts of interest on grant applications and progress reports.
- Research security compliance gaps, including adherence to cybersecurity requirements attached to federal awards.
The undisclosed foreign affiliations enforcement trend
The clearest throughline from the hearing was that foreign-affiliation nondisclosure — not billing fraud or fabricated data alone — is increasingly the theory federal investigators reach for. According to reporting on the hearing, Republican members raised concern that the federal government currently lacks a single, government-wide framework for grant applicants to disclose foreign ties, producing information gaps between funding agencies that make cross-agency pattern detection harder. DOJ’s witness indicated a willingness to work with Congress on closing that gap.
This sits alongside disclosure obligations research institutions already carry, most notably NIH foreign-component disclosure triggers tied to grant applications, and Section 117 of the Higher Education Act, which requires institutions to report foreign gifts or contracts exceeding $250,000 in a calendar year. The hearing’s framing suggests these existing disclosure regimes are increasingly the evidentiary basis for FCA theories when an institution’s certifications turn out to be incomplete or inaccurate — the same dynamic CASRAI has covered in the context of foreign-influence compliance following Confucius Institute closures.
Figures cited at the hearing
Several figures entered the record or were cited in hearing coverage, giving a sense of scale:
- $6.8 billion recovered government-wide under the False Claims Act in fiscal year 2025.
- $233 billion to $521 billion — the wide estimated range cited for total annual government fraud losses across all federal programs, not research funding specifically.
- Roughly $9 million recovered by NSF’s Office of Inspector General across 15 FCA-related settlements over the preceding ten years, per NSF OIG testimony.
- $112 million — Duke University’s 2019 FCA settlement tied to scientific misconduct in federally funded research, cited as a reference point for the scale FCA exposure can reach.
NASA’s Inspector General’s office also indicated it intends to begin conducting site visits to grantees as part of strengthening its oversight capacity.
A partisan fault line: DEI programs and FCA scope
The hearing was not without disagreement over how far FCA enforcement should reach. Committee Democrats, including Rep. Suzanne Bonamici, argued that grant-fraud concerns were being used, in her characterization, as cover for funding cuts, and separately raised concern that the FCA could be turned against institutions over lawful diversity, equity, and inclusion programs. DOJ’s witness stated that lawful DEI programs remain permissible and are not, on their own, an FCA target. Chairman McCormick’s framing was narrower: that oversight mechanisms need to keep pace with the scale of federal research investment.
Research administrators should read this exchange as a signal that FCA-and-research-funding remains a live, contested policy area rather than a settled one — the enforcement priorities discussed at this hearing (foreign-affiliation disclosure, false certifications, cybersecurity compliance) are the areas most likely to see continued DOJ and agency-OIG attention regardless of how the underlying political disagreement resolves.
What this means for research administrators
Nothing announced at this hearing changes the underlying legal standard covered in CASRAI’s FCA research grant compliance guide — but it does confirm where enforcement attention is concentrated going into the second half of 2026:
- Audit your institution’s current-and-pending support, other-support, and foreign-affiliation disclosure processes against actual agency requirements, not just internal habit — gaps between what investigators disclose informally and what’s captured on official forms are exactly the fact pattern the hearing described as an FCA risk.
- Confirm foreign gift and contract reporting under Section 117 of the Higher Education Act ($250,000 threshold) is current and complete institution-wide, not siloed to a single office.
- Treat cybersecurity requirements attached to federal awards as a compliance certification, not just an IT policy matter — the hearing specifically named cybersecurity adherence as an FCA exposure area.
- For institutions with clinical research portfolios, the same enforcement logic extends to billing compliance; see CASRAI’s related guide on False Claims Act liability in clinical trial billing.
For a real, recently resolved example of how a federal falsification finding can play out financially for a research institution — though resolved through an HHS-OIG civil monetary penalty process rather than a DOJ False Claims Act case — see CASRAI’s coverage of Northwestern’s $2.3 million NIH falsification settlement.
Sources
- House Committee on Science, Space, and Technology, Subcommittee on Investigations and Oversight — hearing record, “Safeguarding Federal Research Funds: The False Claims Act’s Role in Combating Grant Fraud,” June 24, 2026.
- AIP FYI, “House Science Republicans Examine Grant Fraud.”
- COSSA, “House Science Investigations and Oversight Subcommittee Holds Hearing on Federal Research Funds.”
